ALK and non-small cell lung carcinoma: More recently, the inhibition of anaplasic lymphoma kinase (ALK) has been reported to result in tumour shrinkage or stable disease in most patients with NSCLC harbouring EML4-ALK fusion genes, but concerned only 2 to 7% of NSCLC [9].